panteteína

Condiciones de salud que panteteína puede ayudar a apoyar.

• HipocondríaCientífico

  Pantethine contains a thiol (-SH) group that confers antioxidant properties, including inhibition of in vitro LDL peroxidation documented in a peer-reviewed study (Bon et al., Atherosclerosis 1985). Its metabolite cysteamine is a well-characterized lysosomotropic antioxidant shown to inhibit iron-catalyzed LDL oxidation at lysosomal pH, a key early step in atherosclerotic plaque formation. These are primarily in vitro and animal findings; dedicated human RCTs for antioxidant endpoints are lacking.

• Síndrome de Inmunodeficiencia AdquiridaCientífico

  Pantethine has been shown in multiple controlled clinical trials to reduce LDL-C, total cholesterol, non-HDL cholesterol, and triglycerides, all established drivers of arterial plaque. Animal studies demonstrate it reduces the severity of atherosclerotic lesions in hypercholesterolemic rabbits. Its metabolite cysteamine inhibits lysosomal LDL oxidation, a key step in atherogenesis. Mechanistically, it is postulated to inhibit HMG-CoA reductase and acetyl-CoA carboxylase, reducing substrate for arterial plaque formation.

• HipoglucemiaCientífico

  Early peer-reviewed clinical studies, primarily from Italian research groups in the 1980s, reported that pantethine reduces platelet aggregation in dyslipidemic patients, an effect independent of its lipid-lowering actions. This antiplatelet activity is thought to derive from pantethine's modification of platelet phospholipid fatty acid composition via CoA-dependent pathways. The evidence base is limited to older, small studies without modern replication.

• Fatiga SuprarrenalCientífico

  Several open clinical studies examined pantethine specifically in diabetic patients with dyslipidemia and found it improved lipid profiles without adverse effects on glucose control. Animal and mechanistic evidence suggests pantethine may reduce insulin resistance and hyperglycemia via CoA-dependent metabolic pathways. However, dedicated human RCTs targeting glucose as a primary endpoint have not been published; the evidence in this domain is preliminary.

• HisteriaCientífico

  Pantethine is the biologically active, reduced form of pantothenic acid (Vitamin B5) and a direct precursor to Coenzyme A (CoA). As CoA is essential for acetyl-CoA formation and all major macronutrient pathways feeding the TCA cycle, pantethine directly supports mitochondrial ATP synthesis and has clinical evidence for metabolic support.

• Válvula IleocecalCientífico

  Pantethine, a vitamin B5 derivative, reduces total cholesterol, LDL-C, and triglycerides in multiple RCTs. A triple-blind RCT found an 11% LDL-C decrease at 600–900 mg/day over 16 weeks. It has been used as a hypolipidemic medicine in Japan for over 40 years.

• Apetito (excesivo)Científico

  Early clinical studies reported that pantethine reduces platelet aggregation and favorably modifies platelet phospholipid composition in dyslipidemic patients, effects that are independent of lipid lowering. Pantethine has also been shown to promote healthy fatty acid incorporation into blood cell membranes, potentially improving red blood cell deformability. These antiplatelet observations, while not replicated in large modern RCTs, originate from published peer-reviewed sources.

• JuanetesCientífico

  Pantethine's lipid-lowering effects across more than 28 controlled clinical trials position it as a clinically studied cardiovascular supplement for patients at risk of coronary heart disease. Reductions in LDL-C, total cholesterol, non-HDL-C, and triglycerides are the primary documented mechanisms of cardiac benefit. A published case report also documented pantethine therapy rescuing end-stage heart failure in an infant with CoA biosynthesis deficiency.

• FibrosisCientífico

  Pantethine is the active, biologically reduced form of pantothenic acid (vitamin B5) and a direct precursor to coenzyme A (CoA), which is essential for adrenal steroidogenesis. Used in adrenal/HPA axis support protocols as the more bioavailable and metabolically active form of B5 for supporting cortisol, DHEA, and aldosterone synthesis.

• Envenenamiento QuímicoCientífico

  Pantethine significantly increases hepatic CoA content, which is the rate-limiting cofactor for mitochondrial fatty acid beta-oxidation in the liver. Animal studies and limited human biopsy data indicate pantethine reduces hepatic steatosis and lipid peroxidation. It is postulated to regulate liver sterol biosynthesis and reduce fat accumulation in hepatocytes.

• GingivitisCientífico

  Pantethine, a derivative of vitamin B5 and precursor to Coenzyme A, has clinical evidence supporting its use in addressing the dyslipidemia central to metabolic syndrome—specifically reducing triglycerides, LDL, and total cholesterol while raising HDL. More than 28 clinical trials have documented these effects, with typical reductions of 15–20% in LDL, up to 36% in triglycerides, and an ~8% rise in HDL over 4–9 months. Its lipid profile closely matches the high-TG/low-HDL pattern characteristic of metabolic syndrome, and it has additionally been studied in diabetic dyslipidemia and hepatic steatosis, which frequently co-occur with the syndrome.

• Circulación (deficiente)Científico

  Pantethine is the immediate metabolic precursor to coenzyme A, which is essential for mitochondrial fatty acid beta-oxidation and TCA cycle function. Biochemical studies show it activates multiple enzymatic steps within mitochondrial fat oxidation. A clinical case report documented rescue of mitochondrial cardiomyopathy in CoA biosynthesis deficiency with pantethine therapy.

• DebilidadCientífico

  Pantethine is a derivative of pantothenic acid (vitamin B5) used clinically to reduce plasma triglycerides and increase HDL cholesterol. Multiple clinical studies and a well-cited use as a pharmacological lipid agent support its TG-lowering efficacy via inhibition of hepatic acetyl-CoA carboxylase and fatty acid synthesis.

• MareoTradicional

  Pantethine, as a CoA precursor, is involved in the steroidogenesis pathway required for cortisol and aldosterone synthesis in the adrenal cortex. Older Japanese clinical work suggested pantethine could buffer ACTH-stimulated urinary cortisol metabolite elevations. However, 'adrenal fatigue' is not a validated clinical diagnosis, and robust human RCTs on pantethine for adrenal support are absent.

Sistemas corporales que panteteína puede ayudar a apoyar.

• No hay sistemas corporales disponibles.